Oncimmune (LON:ONC) Shares Up 14.8% – Still a Buy?

Oncimmune Holdings plc (LON:ONC)’s stock price rose 14.8% on Thursday . The stock traded as high as GBX 1.55 ($0.02) and last traded at GBX 1.55 ($0.02). Approximately 435,299 shares changed hands during trading, a decline of 29% from the average daily volume of 613,270 shares. The stock had previously closed at GBX 1.35 ($0.02).

Oncimmune Stock Performance

The company has a debt-to-equity ratio of -412.06, a quick ratio of 0.63 and a current ratio of 1.14. The company has a fifty day moving average of GBX 9.43 and a two-hundred day moving average of GBX 13.97. The firm has a market capitalization of £1.76 million, a price-to-earnings ratio of 0.17 and a beta of 1.19.

Oncimmune (LON:ONC) last posted its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.